SI1346034T1 - POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA - Google Patents

POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA

Info

Publication number
SI1346034T1
SI1346034T1 SI200130908T SI200130908T SI1346034T1 SI 1346034 T1 SI1346034 T1 SI 1346034T1 SI 200130908 T SI200130908 T SI 200130908T SI 200130908 T SI200130908 T SI 200130908T SI 1346034 T1 SI1346034 T1 SI 1346034T1
Authority
SI
Slovenia
Prior art keywords
polypeptide
vwf
nucleic acid
acid encoding
von willebrand
Prior art date
Application number
SI200130908T
Other languages
English (en)
Inventor
Bernhard Laemmle
Helena Elisabeth Schaller-Gerritsen
Miha Furlan
Peter Turecek
Hans-Peter Schwarz
Friedrich Scheiflinger
Gerhard Antoine
Randolf Kerschbaumer
Luigina Tagliavacca
Klaus Zimmermann
Dirk Voelkel
Original Assignee
Baxter Innovations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1346034(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Innovations Gmbh filed Critical Baxter Innovations Gmbh
Publication of SI1346034T1 publication Critical patent/SI1346034T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
SI200130908T 2000-11-22 2001-11-20 POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA SI1346034T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72125400A 2000-11-22 2000-11-22
US09/833,328 US6926894B2 (en) 2000-11-22 2001-04-12 Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
EP01997546A EP1346034B1 (en) 2000-11-22 2001-11-20 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
PCT/EP2001/013391 WO2002042441A2 (en) 2000-11-22 2001-11-20 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE

Publications (1)

Publication Number Publication Date
SI1346034T1 true SI1346034T1 (sl) 2009-08-31

Family

ID=27110398

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130908T SI1346034T1 (sl) 2000-11-22 2001-11-20 POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA

Country Status (15)

Country Link
US (7) US6926894B2 (sl)
EP (1) EP1346034B1 (sl)
AT (1) ATE423194T1 (sl)
AU (1) AU2002218306A1 (sl)
CZ (1) CZ305602B6 (sl)
DE (1) DE60137710D1 (sl)
DK (1) DK1346034T3 (sl)
ES (1) ES2322126T3 (sl)
HU (1) HU227996B1 (sl)
NZ (1) NZ526616A (sl)
PT (1) PT1346034E (sl)
RU (1) RU2003118441A (sl)
SI (1) SI1346034T1 (sl)
SK (1) SK288119B6 (sl)
WO (1) WO2002042441A2 (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
DE20213920U1 (de) 2002-07-03 2003-01-16 Boehm Martina Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
AU2012203101B2 (en) * 2002-09-25 2014-10-02 Km Biologics Co., Ltd. Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
DE60331666D1 (de) * 2002-09-25 2010-04-22 Chemo Sero Therapeut Res Inst Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
ES2387880T3 (es) 2003-12-22 2012-10-03 Mitsubishi Chemical Medience Corporation Procedimiento de detección de trombosis mediante la medición de la proteasa de escisión del factor de von Willebrand
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
DE602004027314D1 (de) * 2004-07-19 2010-07-01 American Diagnostica Inc Verfahren zur messung von adamts13-aktivität auf der blutplättchenoberfläche.
PL1902141T3 (pl) * 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
ES2644089T3 (es) 2007-12-27 2017-11-27 Baxalta GmbH Procedimientos de cultivo celular
KR101756354B1 (ko) 2009-07-31 2017-07-26 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
KR20220139456A (ko) 2009-09-21 2022-10-14 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
PL2591094T3 (pl) 2010-07-08 2019-02-28 Baxalta GmbH Sposób otrzymywania rekombinowanego adamts13 w linii komórkowej
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
ES2554231T3 (es) 2011-05-19 2015-12-17 Baxalta Incorporated Detección de complejos de ADAMTS13-anticuerpo en circulación
KR102006151B1 (ko) 2012-11-27 2019-10-10 삼성디스플레이 주식회사 터치를 인식하고 전기 촉각 자극을 제공하는 표시 장치 및 그 구동 방법
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
CA3031740A1 (en) 2016-08-04 2018-02-08 Baxalta Incorporated Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
EP4127158A2 (en) 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT406867B (de) * 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US20010049106A1 (en) 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7070532B2 (en) * 2003-08-26 2006-07-04 General Motors Corporation Planetary transmission having a rotating-type torque-transmitting mechanism with a stationary piston

Also Published As

Publication number Publication date
HUP0400588A2 (hu) 2004-06-28
US20050266528A1 (en) 2005-12-01
US6926894B2 (en) 2005-08-09
DK1346034T3 (da) 2009-05-11
ATE423194T1 (de) 2009-03-15
US20080176312A1 (en) 2008-07-24
US7501117B2 (en) 2009-03-10
US8703429B2 (en) 2014-04-22
US7910094B2 (en) 2011-03-22
HU227996B1 (hu) 2012-08-28
PT1346034E (pt) 2009-05-05
ES2322126T3 (es) 2009-06-17
SK288119B6 (sk) 2013-09-03
US20090203110A1 (en) 2009-08-13
CZ20031718A3 (cs) 2004-07-14
WO2002042441A3 (en) 2002-08-08
US20170065686A1 (en) 2017-03-09
SK8022003A3 (en) 2004-04-06
US20140335071A1 (en) 2014-11-13
RU2003118441A (ru) 2004-12-10
DE60137710D1 (de) 2009-04-02
US20090017467A1 (en) 2009-01-15
NZ526616A (en) 2005-04-29
US9309506B2 (en) 2016-04-12
AU2002218306A1 (en) 2002-06-03
EP1346034B1 (en) 2009-02-18
HUP0400588A3 (en) 2006-01-30
CZ305602B6 (cs) 2016-01-06
US20020136713A1 (en) 2002-09-26
US8703426B2 (en) 2014-04-22
WO2002042441A2 (en) 2002-05-30
EP1346034A2 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
PT1346034E (pt) Polipéptido da protease de clivagem do factor de von willebrand (vwf), ácido nucleico que codifica o polipéptido e utilização do polipéptido
ATE389666T1 (de) Hohe expressionsrate von proteinen
DE69518751D1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
DE60235039D1 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
DE69021263T2 (de) Fibronektinbindungsprotein und dessen Herstellung.
HK1013847A1 (en) Gdf-1 and uog-1 proteins
DE60141546D1 (de) Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
DE3853446T2 (de) Fibronectinbindungsprotein und dessen Herstellung.
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DK38889D0 (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
EP1117682A4 (en) NEW PEPTIDES
NZ606260A (en) Novel polypeptides involved in immune response